OCGN250516C500
- 0.31
- +0.04+14.81%
Ocugen Newsroom
Ocugen's Strategic Advancements and Promising Developments Justify Buy Rating
Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
Ocugen Price Target Raised to $7.00/Share From $6.00 by Chardan Capital
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen's Strategic BLA Submissions and Financial Position Support Buy Rating
Ocugen Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Ocugen (OCGN)
Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
Buy Rating for Ocugen Based on Promising OCU410 Study Progress and Geographic Atrophy Treatment Potential
Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Xilio Therapeutics (XLO)
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen Analyst Ratings
HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $8
Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
Ocugen Is Maintained at Buy by Chardan Capital
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $7
Ocugen Analyst Ratings
Ocugen's OCU400: Promising Clinical Efficacy and Strong Buy Rating Amidst Valuation and Safety Confidence
Ocugen Price Target Maintained With a $6.00/Share by Chardan Capital